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Background
Methotrexate (MTX) is the mostly used second line agent
to treat Juvenile idiopathic arthritis (JIA). This study
presents a retrospective data evaluation.
Objectives
To prove the efficacy and safety of MTX in all subtypes of
JIA in a retrospective cohort.
Methods
Single center open-label evaluation of the efficacy and
safety of MTX treatment in patients with JIA where treat-
ment was initiated between 31 st of March 2005 and 31 st
of December 2007.
Results
105 patients were MTX initiated aged between 1 to 17
years. 61 of them were female (58.1%). The mean treat-
ment duration was 13.9 months. The mean MTX dose was
14.7 mg/m2/week. The response to therapy is shown in
table 1, response occurred at months 3 and stayed stable
over the observation period.
Adverse effects (AE) were reported by 41% of the patients,
which were evenly distributed over the observation
period. One severe AE occurred, one patient died with
ALL.
Discussion
In this real world retrospective study of all JIA subsets
MTX appears to be a safe and effective drug.
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Table 1: 
baseline At 3 months At 6 months At 12 months
CHAQ-pain subscale 0.886 0.466 0.386 0.338
CHAQ-disability subscale 0.76 0.491 0.425 0.343
CHAQ-severity subsccale 0.398 0.248 0.184 0.207
Number of swollen joints 2.4 0.8 0.6 0.4
Number of tender joints 2.6 1.4 1.1 0.8
Number of joints with LROM 3.3 2.8 2.4 2.4
Physician global (VAS) 2.4 1.0 0.8 0.6
Elevated CRP 45.7% 14.3% 12.5% 42.9%
Elevated Sedimentation rate 43.8% 17.5% 21.1% 42.1%